Faculty, Staff and Student Publications
Publication Date
6-1-2022
Journal
Leukemia & Lymphoma
Abstract
The beneficial effect of statins on the anti-lymphoma activity of the rituximab-based chemotherapy regimen is controversial. Here, we retrospectively reviewed patients with naïve-treated advanced diffuse large B-cell lymphoma (DLBCL) receiving frontline R-CHOP, and for whom data regarding differential statins use was available at the time of initiation of treatment. We observe that patients treated with statins and R-CHOP experienced a significantly higher CR rate as compared to those who received R-CHOP only. We further show that patients receiving medium or high intensity statins and R-CHOP experienced a significantly higher CR as compared to those treated with R-CHOP. Six-year progression free survival was higher for patients who received medium or higher intensity statins as compared to low or no statins. The potential contribution of cholesterol pathway in doxorubicin sensitivity was supported by in vitro/in vivo studies. Our study suggests that targeting cholesterol-using lovastatin could be a therapeutic strategy to enhance responses to R-CHOP in DLBCL patients.
Keywords
Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lymphoma, Large B-Cell, Diffuse, Prednisone, Retrospective Studies, Rituximab, Treatment Outcome, Vincristine, DLBCL, R-CHOP, chemosensitivity, patient survival, statins.
DOI
10.1080/10428194.2021.2020782
PMID
34969327
PMCID
PMC11973980
PubMedCentral® Posted Date
4-7-2025
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons